Metraipolis › archive › dc_2ea471b40fc1
Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report — Europe PMC PMID:41497777
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41497777
- DOI
- 10.1002/ccr3.71766
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T02:11:49.173Z
- SHA-256 of the archived text
c4159686b369928e1c9b6dc2d7281f926beb7f550b1400eef27e5eda0353c972- Stable URL of this page
https://metraipolis.com/documento/dc_2ea471b40fc1
How to cite
Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report — Europe PMC PMID:41497777 — Europe PMC (en), https://europepmc.org/article/MED/41497777 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2ea471b40fc1 (Metraipolis archive dc_2ea471b40fc1, sha256 c4159686b369928e1c9b6dc2d7281f926beb7f550b1400eef27e5eda0353c972)
BibTeX
@misc{dc2ea471b40fc1,
title = {Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report — Europe PMC PMID:41497777},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41497777},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2ea471b40fc1; sha256 c4159686b369928e1c9b6dc2d7281f926beb7f550b1400eef27e5eda0353c972},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41497777. Agents can read the archived copy with the MCP tool read_document.